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Balancing diversity and tolerance: lessons from 
patients with systemic lupus erythematosus
 
Annett M. Jacobi and Betty Diamond
 
The autoimmune disease systemic lupus erythematosus (SLE) is caused by a 
failure of B cell tolerance. Recent studies in mouse models of SLE have 
identified several distinct tolerance checkpoints that must each function 
appropriately to protect against disease. However, studies of B cell repertoire 
selection in humans are essential to understand which checkpoints are 
defective in human autoimmune diseases.
 
The major challenge of the immune
system is to defend the host against mi-
crobial pathogens while protecting itself
from its own arsenal. Meeting this
challenge requires down-regulation of
autoreactivity. For B cells, autoreactivity
is generated at two stages during differ-
entiation—first in the bone marrow and
again in the germinal center response.
Whereas hyperactivity of B cells
and increased antibody production in
SLE have been extensively described,
the mechanisms underlying the failure
of tolerance in SLE remain uncertain.
Mouse models have taught us two critical
lessons with regard to B cell selection.
First, there are many tolerance check-
points during B cell maturation. Second,
autoreactive B cells that escape toler-
ance may mature to be autoantibody-
secreting cells with the phenotypic
characteristics of any B cell subset: B1,
marginal zone (MZ) B cells, short-lived
plasma cells, or germinal center–matured
long-lived plasma cells. Thus, one impor-
tant implication from mouse studies is
that we should anticipate extensive
heterogeneity in patients with lupus,
with respect to both defects in B cell
tolerance and the differentiation state
of the autoreactive B cells. Here we
will discuss recent insights into the stages
in development at which B cell autore-
activity can emerge, and new data that
provide clues to the stages at which B
cell tolerance breaks down in patients.
 
Checkpoints during B cell development
 
During B cell development a delicate
balance of proliferation and apoptosis is
required to shape a highly diversified
antibody repertoire. The B cell receptor
(BCR) is the central regulator of selec-
tion processes. Normally, inappropriate
tonic signaling or cross-linking of the
BCR by antigen results in receptor ed-
iting. This process involves the rear-
rangement of a new light chain gene to
generate an antibody with a new anti-
genic specificity or clonal deletion of
immature B cells in the bone marrow.
Although there is evidence that receptor
editing also occurs in SLE patients,
whether it functions to eliminate autore-
activity appropriately is not known.
To develop from the immature
state in the bone marrow to the mature
naive state in the peripheral lymphoid
organs, a B cell must survive three
checkpoints (Fig. 1). The first check-
point is between the immature cell in
the bone marrow and the transitional
T1 cell in the spleen. The second is be-
tween the T1 and more mature T2/3
state, and the third is between the T2/
T3 stage and mature MZ and B1 and
follicular B cells. Negative selection at
each of these checkpoints is mediated
by BCR signaling and is generally con-
sidered to be a B cell intrinsic property,
although extrinsic factors like the female
sex hormone estradiol can diminish the
BCR signal and thereby diminish neg-
ative selection (1).
T2/T3 cells can be rescued from
negative selection by costimulatory sig-
nals. CD40 engagement by CD40
ligand (CD40L) can rescue B cells des-
tined to undergo BCR-mediated apop-
tosis. Several reports suggest that costim-
ulatory molecules are overexpressed or
dysregulated in SLE, which might ex-
plain the survival of autoreactive transi-
tional B cells (2, 3). The hormone pro-
lactin, which is elevated in 
 
 
 
25% of
lupus patients, causes an increase in the
number of autoreactive follicular B
cells. This increase is T cell dependent
and appears to be related to enhanced
CD40–CD40L interactions (4). B cell
activating factor of the tumor necrosis
factor family (BAFF) can also enhance
the survival of autoreactive transitional
B cells in mice (5). As BAFF is found in
high concentrations in sera of patients
with SLE, it may contribute to defective
B cell tolerance in these patients (6).
 
Checkpoints involving mature 
B cell subsets
 
There are three important populations
of mature immunocompetent B cells:
B1, MZ, and follicular B cells. Under-
standing B cell defects in SLE may well
require identifying which B cell subset
is responsible for autoantibody produc-
tion, as mouse models have clearly
shown that all three subsets can produce
pathogenic autoantibodies.
 
B1 cells
 
B1 cells express CD5, are restricted in
BCR diversity, and fail to generate a
memory population. In nonautoim-
mune mice, autoreactive B cells bearing
low-affinity BCRs usually home to the
peritoneal cavity as B1 cells. The auto-
antibodies made by these cells are
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thought to help avoid pathogenic au-
toreactivity by assisting in the clearance
of apoptotic cells (7). In female, phy-
toestrogen-treated, lupus-prone BWF1
mice, B1 cells produce pathogenic
autoantibodies (8). Likewise, in the
moth-eaten mice, which are deficient
in the inhibitory phosphatase SHP-1,
high-affinity IgM antibodies that rec-
ognize double-stranded (ds)DNA are
produced by the B1 cell population (9).
A comparable human B cell sub-
population also expresses CD5. Hu-
man CD5
 
 
 
 B cells produce polyreac-
tive, low-affinity IgM antibodies using
germline-encoded V genes. In SLE,
anti-DNA antibodies may be produced
by both CD5
 
 
 
 and CD5
 
 
 
 B cells.
CD5
 
 
 
 B cells may not be the precur-
sors of the CD5
 
 
 
 antibody-secreting
cells, which produce high-affinity, im-
munoglobulin (Ig) class-switched anti-
DNA antibodies. Human CD5
 
 
 
 B
cells can be induced to differentiate
into cells with features of germinal
center (GC) cells (10) and autoreactive
CD5
 
 
 
 B cells carrying somatically mu-
tated V genes have been described in
rheumatoid arthritis (11), suggesting
that there might be circumstances un-
der which CD5
 
 
 
 B cells enter GCs
or undergo ectopic somatic mutation.
These findings may indicate that im-
paired regulation of polyreactive CD5
 
 
 
B cells, or a B cell abnormality that be-
gins as far back as the generation of the
B1 cell repertoire, may be involved in
the development of SLE. One caveat is
that it is not clear if CD5
 
 
 
 cells in hu-
man are the same as B1 cells in mice or
whether they might also represent
post-GC anergic B cells.
Autoantibody secretion by CD5
 
 
 
 B
cells is normally observed as a transient
event that accompanies certain infec-
tions. Cold agglutinins are pathogenic
IgM antilymphocyte antibodies that use
 
VH4-34
 
 rearrangements in the germ-
line configuration and are made by a
CD5
 
 
 
 population. If B cell tolerance is
intact, 
 
VH4-34
 
–expressing, CD5
 
 
 
 B
cells are present in the naive repertoire
but are excluded from GC reactions.
In SLE patients, however, 
 
VH4-34
 
–
expressing B cells enter GCs and con-
tribute to the memory B cell pool (12).
This observation suggests that the bar-
rier which keeps autoreactive CD5
 
 
 
cells from entering the GC is an essen-
tial checkpoint in B cell development
and that, for unknown reasons, this
barrier may be broken in SLE.
 
Marginal zone B cells
 
Some anti-DNA antibodies are pro-
duced by MZ B cells in NZB/WF1
mice (13) and in other mouse models
of lupus (1). MZ B cell development
depends on BAFF, and these cells are
easily activated by dendritic cells and
mature rapidly into plasmablasts (14).
MZ B cells also act as antigen-present-
ing cells (APCs) and activate T cells, as
they express costimulatory molecules
on their surface (15). Recent studies in
lupus-prone mice suggest that some B
cells, possibly MZ B cells, are able to
generate T cell–independent autoim-
mune responses and can undergo heavy
chain class-switching and somatic mu-
tation in extrafollicular regions of the
spleen (16). MZ B cells have been
shown to initiate GC formation (14).
But what regulates their differentiation
to either a GC or an extrafollicular fo-
cus of antibody production is not
known. In humans, MZ B cells appear
to be present in the circulation as
CD1c
 
 
 
IgD
 
low
 
IgM
 
 
 
CD27
 
 
 
 cells (17)
and can populate all secondary lym-
phoid organs. It remains to be eluci-
dated to what extent MZ B cells con-
tribute to the secretion of pathogenic
autoantibodies in human SLE; how-
ever, these highly flexible actors have
all the characteristics required to break
T cell tolerance.
 
Germinal center cells
 
The GC is another critical checkpoint
in B development. After antigen en-
counter and T cell help, follicular B
cells generate a GC to mount an affin-
ity-matured antibody response and
generate memory B cells. During so-
matic hypermutation and Ig class-
switching, a stringent but poorly un-
derstood balance of proliferative and
apoptotic signals is required to guaran-
tee the expansion of B cells with high
affinity to foreign antigens and prevent
the survival of autoreactive B cells.
During immune responses to foreign
antigens in mice, as many as 40% of the
GC B cells display potentially patho-
genic autoreactivity (18). Since many
Figure 1. Negative selection checkpoints in B cell development. There are two points of BCR 
diversification—initial receptor rearrangement in the bone marrow and somatic hypermutation during 
the germinal center reaction. Each is followed by negative selection of autoreactive cells. Negative 
selection, receptor editing, anergy, or deletion occur in immature and transitional B cells after BCR 
engagement. The mechanisms for negative selection of autoreactive cells in GCs are not known. 
HC, heavy chain; LC, light chain. 
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autoantibodies in SLE display extensive
somatic mutation, there is a strong pre-
sumption of a defect in negative selec-
tion of GC-matured B cells. GC cells
surviving negative selection enter the
pool of long-lived memory or plasma
cells, which is relatively refractory
to many immunosuppressive therapies.
Very little is understood about the pro-
cess of negative selection in GCs, al-
though there is some new evidence
suggesting that receptor editing may
also function at this point to eliminate
autoreactivity (19). The Fc receptor
Fc
 
 
 
2RIIB may also mediate an impor-
tant inhibitory pathway at this stage of
B cell differentiation, as immune com-
plexes may be critical in regulating B
cell survival within the GC. Lack of
expression of Fc
 
 
 
2RIIB
 
 
 
causes an ac-
cumulation of plasma cells secreting
anti-DNA antibodies in mice (20), and
polymorphisms of 
 
Fc
 
 
 
2RIIB
 
 have been
associated with autoimmunity in mice
and man. It is also possible that the
presence of autoreactive T cells in SLE
may serve to mediate positive selection
of autoreactive GC B cells.
 
New insights from patient studies
 
Nussenzweig and colleagues have pre-
viously reported that more than half of
all newly generated immature B cells in
healthy individuals appear to be polyre-
active and capable of binding self-anti-
gen (21). However, only a small per-
centage of immature/transitional B
cells survive the process of ligand-
dependent selection and enter the pool
of mature naive B cells.
In a recent issue of the 
 
JEM
 
, the same
group described the B cell repertoire at
the transitional and naive stage in three
newly diagnosed, untreated patients with
SLE (22). In two patients, they did not
find the anticipated diminution in the
frequency of autoreactive B cells as the
cells matured from the transitional to
the naive stage. In the third patient, this
checkpoint appeared to be partly intact.
However, this patient had an higher fre-
quency of self-reactive B cells among
new B cell emigrants, consistent with a
defect in early B cell tolerance in the
bone marrow. All three patients displayed
an increased frequency of autoreactive
cells in the repertoire of immunocompe-
tent naive B cells. Although the demon-
stration of a failure to eliminate autoreac-
tive B cells from the bone marrow or the
transitional compartment is important, it
does not allow the precise identification
of the tolerance defect. Furthermore, it
remains to be investigated whether this
failure is B cell intrinsic or a consequence
of a factor extrinsic to the B cell itself that
either modulates the strength of BCR
signaling or engages a rescue pathway.
The definition of autoreactivity in
this paper (22) is the binding of serum
antibodies to a lysate of Hep 2 cells in an
ELISA. The antigens are, therefore, both
nuclear and cytoplasmic. When the au-
toreactive antibodies were studied in de-
tail, almost all were found to be polyreac-
tive and to bind multiple self-antigens
including single-stranded (ss)DNA and
insulin, but rarely to dsDNA, which is
the characteristic autoantigen in SLE. Fi-
nally, the study examined V gene usage
in autoantibodies and found it to be het-
erogeneous, suggesting a polyclonal re-
sponse to antigen rather than the prolifer-
ation of a single dysregulated B cell clone.
Because some studies have demonstrated
long heavy chain CDR3 regions in lupus
autoantibodies and an increased fre-
quency of arginine residues in anti-DNA
antibodies, the authors examined CDR3
regions in their panel of autoantibodies.
They found these features to be quite
variable. Samuels et al. have described a
similar defect in negative selection of B
cells in patients with rheumatoid arthritis
(RA; reference 23). It will be important
to learn at which state polyreactivity is
lost, and, for example, when anti-insulin
antibodies disappear from the repertoire
of patients with either SLE or RA. It is
possible in SLE that the naive B cells that
are preferentially activated are those
which bind RNA or DNA. For these
cells, encounter with antigen would acti-
vate BCR signaling and Toll-like recep-
tors—innate pathogen receptors that may
also recognize self-DNA and RNA—
and lead to cellular activation (24).
RNA- and DNA-binding cells may,
therefore, undergo positive selection and
be rescued from deletion, whereas B cells
binding self-antigens that do not trigger
Toll-like receptors may be neither res-
cued nor activated. What mediates posi-
tive selection in RA is less clear.
It is not yet clear whether the
polyreactive autoreactive B cells that are
present at increased frequency in pa-
tients with SLE and RA reflect a defect
in negative selection that correlates with
the development of disease or whether
they represent the precursors of the B
cells that produce pathogenic autoanti-
bodies. There is little to guide us in ad-
dressing this question, except the im-
portant observation that both murine
and human antibodies to dsDNA in
SLE can be derived from an antibody
that in the germline configuration had
no specificity for DNA and no apparent
autoreactivity (25). This observation re-
calls the Jerne hypothesis that all germ-
line antibodies are inherently autoreac-
tive and mutation leads away from
autoreactivity. The opposite hypothesis
has also been posed, and the answer may
be that both hypotheses are correct. It is
highly likely that some pathogenic au-
toantibodies arise from naive B cells that
are autoreactive and others do not.
 
Future questions
 
Studies of B cells in human SLE are still
in their infancy. There is already evi-
dence that more than one defect in se-
lection contributes to an increased fre-
quency of autoreactive B cells. It is likely
that the study of more patients will re-
veal an even wider array of regulatory
defects. In fact, it is likely that lupus pa-
tients will be at least as heterogeneous as
mouse models of SLE, and that further
study will reveal both genetically deter-
mined and extrinsically induced alter-
ations in the B cell repertoire. Of note,
10–20 percent of individuals receiving
interferon therapy or TNF blockade
produce lupus-like antibodies and some
develop symptomatic lupus (26), sug-
gesting that there can be externally in-
duced changes in the homeostatic mech-
anisms that regulate B cell repertoire.
There are many unanswered ques-
tions regarding lupus autoantibodies.
One question, for example, relates to
the differential regulation of autoanti-
bodies with different antigenic specifici-
ties. In SLE, the dominant autospecific-
ities are to nuclear antigens. Antibodies
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to dsDNA play a major role in disease,
since they are found in many affected
tissues and can clearly contribute to kid-
ney disease. Their titer usually corre-
lates with disease activity and can be
used to monitor patients during immu-
nosuppressive therapy. However, some
patients maintain high titers of anti-
dsDNA antibodies, despite immuno-
suppressive therapy. In addition, there
are other autoantibodies characteristic of
SLE, such as antiphospholipid antibod-
ies or antibodies to ribonucleoproteins,
that do not display fluctuating titers reg-
ulated either by disease activity or by
immunosuppressive therapy. This clini-
cal observation cannot be explained by
current knowledge of B cell selection
and activation. It seems clear that we
will need additional studies that focus
on particular autospecificities to fully
understand B cell dysregulation in SLE.
Furthermore, determining where and
why the spectrum of autoantigenic
specificities in SLE and RA, and per-
haps other diseases characterized by au-
toantibody production, diverge will be
a challenge for future studies.
Studies of GC selection are, like-
wise, crucial but are difficult to per-
form, as it is difficult to obtain access to
the necessary human lymphoid tissue.
Yet, there are many hints in the litera-
ture that a critical defect in lupus occurs
during GC B cell selection. We need to
learn whether B cell selection in indi-
vidual lupus patients is aberrant only in
the immature or naive repertoire, only
in the GC repertoire, or whether de-
fects in selection always affect both the
pre- and post-GC B cell repertoire.
More studies of B cell selection, com-
bined with molecular analyses of BCR
signaling pathways, may help pheno-
type SLE patients in ways that will per-
mit an understanding of the heteroge-
neity of the disease. A description of the
clinical phenotypic features that associ-
ate with each regulatory defect will lead
us toward patient-specific therapies that
may eliminate autoreactivity while pre-
serving immunocompetence.
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